PL3319956T3 - Podstawione pochodne oksopirydyny - Google Patents

Podstawione pochodne oksopirydyny

Info

Publication number
PL3319956T3
PL3319956T3 PL16734672T PL16734672T PL3319956T3 PL 3319956 T3 PL3319956 T3 PL 3319956T3 PL 16734672 T PL16734672 T PL 16734672T PL 16734672 T PL16734672 T PL 16734672T PL 3319956 T3 PL3319956 T3 PL 3319956T3
Authority
PL
Poland
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
oxopyridine
Prior art date
Application number
PL16734672T
Other languages
English (en)
Polish (pl)
Inventor
Eloisa JIMENEZ NUNEZ
Jens Ackerstaff
Susanne Röhrig
Alexander Hillisch
Katharina MEIER
Stefan Heitmeier
Adrian Tersteegen
Jan Stampfuss
Pascal ELLERBROCK
Daniel Meibom
Dieter Lang
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of PL3319956T3 publication Critical patent/PL3319956T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL16734672T 2015-07-09 2016-07-05 Podstawione pochodne oksopirydyny PL3319956T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP16157350 2016-02-25
PCT/EP2016/065787 WO2017005725A1 (en) 2015-07-09 2016-07-05 Substituted oxopyridine derivatives
EP16734672.5A EP3319956B1 (en) 2015-07-09 2016-07-05 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
PL3319956T3 true PL3319956T3 (pl) 2021-07-05

Family

ID=56345141

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16734672T PL3319956T3 (pl) 2015-07-09 2016-07-05 Podstawione pochodne oksopirydyny

Country Status (39)

Country Link
US (4) US10421742B2 (OSRAM)
EP (1) EP3319956B1 (OSRAM)
JP (1) JP6871180B2 (OSRAM)
KR (1) KR102596164B1 (OSRAM)
CN (2) CN113292539B (OSRAM)
AU (1) AU2016289746B2 (OSRAM)
CA (1) CA2990901C (OSRAM)
CL (1) CL2018000039A1 (OSRAM)
CO (1) CO2018000113A2 (OSRAM)
CR (1) CR20180017A (OSRAM)
CU (1) CU24512B1 (OSRAM)
CY (1) CY1123996T1 (OSRAM)
DK (1) DK3319956T3 (OSRAM)
DO (1) DOP2018000004A (OSRAM)
EA (1) EA036208B1 (OSRAM)
EC (1) ECSP18001308A (OSRAM)
ES (1) ES2856554T3 (OSRAM)
GE (1) GEP20197046B (OSRAM)
HR (1) HRP20210459T1 (OSRAM)
HU (1) HUE053552T2 (OSRAM)
IL (1) IL256556B (OSRAM)
JO (1) JO3703B1 (OSRAM)
LT (1) LT3319956T (OSRAM)
MA (1) MA42376B1 (OSRAM)
MX (1) MX377903B (OSRAM)
MY (1) MY196640A (OSRAM)
NI (1) NI201800001A (OSRAM)
PE (1) PE20180538A1 (OSRAM)
PH (1) PH12018500057A1 (OSRAM)
PL (1) PL3319956T3 (OSRAM)
RS (1) RS61584B1 (OSRAM)
SI (1) SI3319956T1 (OSRAM)
SV (1) SV2018005610A (OSRAM)
TN (1) TN2018000011A1 (OSRAM)
TW (1) TWI717367B (OSRAM)
UA (1) UA122341C2 (OSRAM)
UY (1) UY36780A (OSRAM)
WO (1) WO2017005725A1 (OSRAM)
ZA (1) ZA201800826B (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2722423T3 (es) * 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
US20190119213A1 (en) * 2015-03-19 2019-04-25 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
HUE057289T2 (hu) 2016-08-31 2022-05-28 Jiangsu Hengrui Medicine Co Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása
HRP20220565T1 (hr) * 2018-03-15 2022-06-10 Bayer Aktiengesellschaft Postupak pripreme dva derivata 4-{[(2s)-2-{4-[5-klor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
ES2922533T3 (es) 2018-04-10 2022-09-16 Bayer Pharma AG Un derivado de oxopiridina sustituido
EP3822264A4 (en) 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS
AR115870A1 (es) 2018-07-31 2021-03-10 Sumitomo Chemical Co MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
KR20210105939A (ko) * 2018-12-17 2021-08-27 바이엘 악티엔게젤샤프트 혈전성 또는 혈전색전성 장애 및/또는 혈전성 또는 혈전색전성 합병증의 치료 및/또는 예방을 위한 치환된 옥소피리딘 유도체
AR117435A1 (es) 2018-12-21 2021-08-04 Bayer Ag Derivados de oxopiridina sustituidos
EP3898634A1 (en) 2018-12-21 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
JP7450024B2 (ja) * 2019-09-27 2024-03-14 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド FXIa阻害剤及びその調製方法と医薬用途
EP4215525A4 (en) 2020-09-17 2024-08-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Piperazine derivative, preparation method therefor and use thereof
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CA3212645A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
PE20250018A1 (es) * 2021-03-09 2025-01-07 Bayer Ag Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
CN113666826B (zh) * 2021-07-30 2024-03-26 五邑大学 一种芳基或杂芳基甲氧基化反应的方法
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) * 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116262736B (zh) * 2022-12-26 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN120936342A (zh) 2023-03-31 2025-11-11 拜耳公司 包含(4s)-24-氯-4-乙基-73-氟-35-甲氧基-32,5-二氧代-14-(三氟甲基)-32h-6-氮杂-3(4,1)-吡啶-1(1)-[1,2,3]三唑-2(1,2),7(1)-二苯杂七蕃-74-甲酰胺的药物剂型
WO2024251276A1 (zh) 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1,2,3-三唑的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
EP1526131A1 (en) 2003-10-22 2005-04-27 Graffinity Pharmaceuticals Aktiengesellschaft Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
NZ572418A (en) 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 XIa 억제제로서 피리디논 및 피리미디논 유도체
BR112015002081A2 (pt) * 2012-08-03 2017-07-04 Bristol Myers Squibb Co di-hidropiridona p1 como inibidores de fator xia
WO2014159218A1 (en) 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions
EP2978425B1 (en) * 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JP6410819B2 (ja) 2013-07-23 2018-10-24 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
EP3138839B1 (en) 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
ES2722423T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
EP3197891B1 (de) 2014-09-24 2018-11-21 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
US10071995B2 (en) * 2014-09-24 2018-09-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046164A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046166A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US10336730B2 (en) * 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors

Also Published As

Publication number Publication date
JO3703B1 (ar) 2021-01-31
EA036208B1 (ru) 2020-10-14
CR20180017A (es) 2018-03-07
KR20180026761A (ko) 2018-03-13
CN113292539B (zh) 2023-12-22
CU20180001A7 (es) 2018-06-05
CN108026072A (zh) 2018-05-11
AU2016289746A1 (en) 2018-01-25
UA122341C2 (uk) 2020-10-26
DK3319956T3 (da) 2021-03-29
US10421742B2 (en) 2019-09-24
PH12018500057A1 (en) 2018-07-09
ES2856554T3 (es) 2021-09-27
CA2990901A1 (en) 2017-01-12
CO2018000113A2 (es) 2018-06-12
UY36780A (es) 2017-01-31
US20190367478A1 (en) 2019-12-05
AU2016289746B2 (en) 2020-08-20
DOP2018000004A (es) 2018-01-31
HRP20210459T1 (hr) 2021-05-14
GEP20197046B (en) 2019-12-10
MA42376A (fr) 2018-05-16
IL256556B (en) 2021-02-28
EP3319956B1 (en) 2021-01-06
ECSP18001308A (es) 2018-03-31
LT3319956T (lt) 2021-02-10
US20250282748A1 (en) 2025-09-11
IL256556A (en) 2018-02-28
MY196640A (en) 2023-04-25
CY1123996T1 (el) 2022-07-22
TWI717367B (zh) 2021-02-01
WO2017005725A1 (en) 2017-01-12
MA42376B1 (fr) 2021-04-30
CA2990901C (en) 2024-11-12
BR112018000209A2 (pt) 2018-09-04
EA201890111A1 (ru) 2018-06-29
CU24512B1 (es) 2021-05-12
HUE053552T2 (hu) 2021-07-28
NI201800001A (es) 2018-10-19
JP6871180B2 (ja) 2021-05-12
ZA201800826B (en) 2021-08-25
CN113292539A (zh) 2021-08-24
TW201706261A (zh) 2017-02-16
PE20180538A1 (es) 2018-03-20
NZ739109A (en) 2024-09-27
US11180471B2 (en) 2021-11-23
HK1255045A1 (zh) 2019-08-02
JP2018519323A (ja) 2018-07-19
CN108026072B (zh) 2021-08-17
CL2018000039A1 (es) 2018-07-13
SI3319956T1 (sl) 2021-02-26
TN2018000011A1 (en) 2019-07-08
EP3319956A1 (en) 2018-05-16
RS61584B1 (sr) 2021-04-29
SV2018005610A (es) 2018-04-27
US20230024752A1 (en) 2023-01-26
KR102596164B1 (ko) 2023-11-01
MX2018000076A (es) 2018-02-26
US20180194745A1 (en) 2018-07-12
MX377903B (es) 2025-03-10

Similar Documents

Publication Publication Date Title
ZA201800826B (en) Substituted oxopyridine derivatives
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
IL253381A0 (en) History of h9-pyrrolo-dipyridine
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
AU361999S (en) Ballustrade
PT3097076T (pt) Novos derivados cyp-eicosanoides
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
ZA201802194B (en) Aminoazole derivative
PT3319956T (pt) Derivados de oxopiridina substituída
AU5511P (en) PTK647 Epichloe coenophiala
AU366552S (en) Nutblock
AU367131S (en) USB-charger
AU365008S (en) Playsuit
AU2015165V (en) PWBC12 Chamelaucium uncinatum
AU362754S (en) Playsuit
AU2015211V (en) SGIBL01-0 Scabiosa columbaria
AU2015212V (en) SGIPU2-0 Scabiosa columbaria
AU364191S (en) Tallboy
AU2015003V (en) PencilGL Guichenotia macrantha